Search





Search





Markets
/
Stocks
/
nasdaq-tnxp
/

Tonix Pharmaceuticals Holding Corp

TNXP

Add to Watchlist

15.740USD

+1.650+11.71%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

250.91MMarket Cap

LossP/E TTM



Tonix Pharmaceuticals Holding Corp

15.740

+1.650+11.71%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Tonix Pharmaceuticals Holding Corp

Currency: USD Updated: 2026-05-15

Key Insights

Tonix Pharmaceuticals Holding Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 103 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 46.25.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Tonix Pharmaceuticals Holding Corp's Score

Industry at a Glance

Industry Ranking

103 / 155

Overall Ranking

315 / 4482

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Tonix Pharmaceuticals Holding Corp Highlights

StrengthsRisks

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 68.73% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 13.11M.

Undervalued

The company’s latest PE is -1.07, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 4.66M shares, increasing 30.25% quarter-over-quarter.

Held by Murray Stahl

Star Investor Murray Stahl holds 1.64K shares of this stock.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

46.250

Target Price

+228.25%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Tonix Pharmaceuticals Holding Corp is 6.98, ranking 124 out of 155 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 6.88M, representing a year-over-year increase of 183.16%, while its net profit experienced a year-over-year increase of 138.84%.

Score

Industry at a Glance

Previous score

6.98

Change



Financials

9.87

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.60

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.88

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.43

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.14

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Tonix Pharmaceuticals Holding Corp's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Tonix Pharmaceuticals Holding Corp is 8.02, ranking 32 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -1.07, which is -104.42% below the recent high of 0.05 and -2.81% above the recent low of -1.10.

Score

Industry at a Glance

Previous score

8.02

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 103/155

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Tonix Pharmaceuticals Holding Corp is 8.00, ranking 58 out of 155 in the Pharmaceuticals industry. The average price target is 65.00, with a high of 70.00 and a low of 64.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

46.250

Target Price

+228.25%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Tonix Pharmaceuticals Holding Corp

TNXP

Amgen Inc

AMGN

Biogen Inc

BIIB

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

Vertex Pharmaceuticals Inc

VRTX

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Tonix Pharmaceuticals Holding Corp is 1.45, ranking 154 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 17.04 and the support level at 13.22, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.35

Change

0.1

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.433

Buy

RSI(14)

62.659

Neutral

STOCH(KDJ)(9,3,3)

76.042

Buy

ATR(14)

1.075

High Vlolatility

CCI(14)

164.375

Buy

Williams %R

2.130

Overbought

TRIX(12,20)

0.157

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

14.212

Buy

MA10

13.999

Buy

MA20

13.526

Buy

MA50

13.732

Buy

MA100

14.857

Buy

MA200

20.205

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Tonix Pharmaceuticals Holding Corp is 3.00, ranking 94 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 32.65%, representing a quarter-over-quarter increase of 27.35%. The largest institutional shareholder is Steven Cohen, holding a total of 620.03K shares, representing 3.89% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

807.88K

+27.44%

Point72 Asset Management, L.P.

Star Investors

620.03K

Geode Capital Management, L.L.C.

271.90K

+35.32%

State Street Investment Management (US)

191.85K

+25.77%

UBS Financial Services, Inc.

79.44K

+91.96%

Northern Trust Investments, Inc.

172.98K

+3.99%

Balyasny Asset Management LP

185.35K

Davidson Kempner Capital Management LP

90.01K

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Tonix Pharmaceuticals Holding Corp is 4.26, ranking 89 out of 155 in the Pharmaceuticals industry. The company's beta value is 1.71. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.